Streetbeat News

Analyst Ratings

TSLA

HSBC analyst Michael Tyndall has reiterated a 'Reduce' rating on Tesla (NASDAQ:TSLA) and maintained a price target of $124.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:33 pm

DPZ

B of A Securities has maintained a Buy rating on Domino's Pizza (NYSE:DPZ) but has lowered the price target from $582 to $557.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:30 pm

HUYA

HSBC analyst Ritchie Sun has downgraded HUYA from Buy to Hold, setting a price target of $4.7.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:28 pm

DAL

B of A Securities analyst Andrew Didora maintains a Buy rating on Delta Air Lines and raises the price target from $55 to $60.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:28 pm

NFLX

Guggenheim analyst Michael Morris has maintained a Buy rating on Netflix and raised the price target from $735 to $810.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:26 pm

UBER

B of A Securities analyst Justin Post has reiterated a Buy rating on Uber Technologies, maintaining a price target of $88.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:25 pm

IOT

TD Cowen analyst J. Derrick Wood has maintained a Buy rating on Samsara (NYSE:IOT) and raised the price target from $46 to $56.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:23 pm

LOW

B of A Securities analyst Elizabeth Suzuki maintains a Buy rating on Lowe's Companies and raises the price target from $275 to $305.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:21 pm

CPRT

Copart Inc. (NASDAQ:CPRT) has seen a stock price increase of 11.87% over the past month and 20.48% over the past year. Its P/E ratio of 39.72 is lower than the industry average of 44.92, suggesting potential undervaluation or weak growth prospects. Investors are advised to consider multiple financial metrics and industry trends when evaluating the stock.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 5:15 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating for Alnylam Pharmaceuticals, maintaining a price target of $220.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:12 pm